Cutler Group LP Adaptimmune Therapeutics PLC Call Options Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Jan 18, 2022	SELL	$3.5 - $5.68 $3,500 - $5,680	-1,000 Reduced 23.26%	3,300 $0
Q3 2021 Oct 26, 2021	SELL	$3.44 - $6.37 $18,576 - $34,398	-5,400 Reduced 55.67%	4,300 $0
Q2 2020 Jul 22, 2020	BUY	$2.58 - $12.1 $12,126 - $56,870	4,700 Added 94.0%	9,700 $30,000
Q1 2020 May 07, 2020	BUY	$1.2 - $4.52 $5,160 - $19,435	4,300 Added 614.29%	5,000 $3,000
Q1 2018 May 11, 2018	BUY	$7.1 - $11.56 $4,260 - $6,936	600 Added 600.0%	700 $1,000
Q3 2017 Oct 17, 2017	BUY	$4.93 - $8.93 $493 - $893	100	100 $0

145M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $99.7M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.